KLKarin Littmann

Karin Littmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karin Littmann has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Jonas Brinck

    Department of Medicine-H7 Huddinge, Karolinska Institutet , Stockholm

    6 shared publications
  • Daniel Eriksson Hogling

    Department of Medicine Huddinge, Karolinska Institutet, Department of Endocrinology Karolinska University Hospital, Stockholm, Sweden

    5 shared publications
  • Gustav Kindborg

    Department of Medicine Huddinge, Karolinska Institutet , Endokrinexpeditionerna C2:94, Karolinska Universitetssjukhuset Huddinge, 141 86 Stockholm

    3 shared publications
  • Anders Grubb

    Department of Clinical Chemistry Skåne University Hospital Lund University Lund Sweden

    2 shared publications
  • Anders Larsson

    Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 75185 Uppsala, Sweden

    2 shared publications
  • Daniel P Andersson

    Department of Medicine Huddinge, Karolinska Institutet , Endokrinexpeditionerna C2:94, Karolinska Universitetssjukhuset Huddinge, 141 86 Stockholm

    2 shared publications

Latest Publications

  • Open Access

    Lipoprotein(a) cascade screening in coronary artery disease

    by Karin Littmann, Daniel Eriksson Hogling, Mustafa Suhel, Kamilla Juhlin, Pinar Kara, Matteo Bottai, Niclas Svedberg, Anna M. Nordenskjöld, Mattias Ekström, Linda Mellbin, et al.

  • Open Access

    Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study

    by Gustav Kindborg, Daniel Eriksson Hogling, Henrike Häbel, Jane Yan, Teresa Hallerbäck, Örjan Lindhe, Emil Hagström, Daniel P Andersson, Karin Littmann, Jonas Brinck

    Background and Aims: Lipoprotein(a) [Lp(a)] levels are genetically determined and causal in the development of atherosclerotic cardiovascular disease. Whether first-degree relatives (FDRs) of individuals with elevated Lp(a) levels (≥80th percentile) have an increased cardiovascular disease risk is unknown. Methods: Based on 41 304 indexes with a routine plasma Lp(a) measurement, 61 715 FDRs without a measured Lp(a) aged 35–69 years (49% women) were identified in the Swedish STRIREG cohort. First-degree relatives were stratified according to index Lp(a) percentile level: <50th, 50–<80th, 80–<95th, and ≥95th. In competing risk-adjusted cumulative incidence and adjusted Cox proportional hazards regressions, the association between Lp(a) strata and major adverse cardiovascular events (MACE; cardiovascular death, myocardial infarction, ischaemic stroke, coronary revascularization) was investigated. In a nested analysis of 4243 indexes with a first-degree relationship with another index, the concordance of plasma Lp(a) levels was assessed. Results: During a median follow-up of 19 (11–26) years, 2043 FDRs had a MACE. The cumulative incidences of MACE in FDR until age of 65 were 6.2%, 7.0%, 7.5%, and 8.1% by increasing index Lp(a) level strata (P < .001). Compared with FDR in the lowest Lp(a) stratum, there was a higher hazard ratio for MACE by increasing Lp(a) stratum: 1.08 (95% confidence interval, 0.97–1.19), 1.30 (1.15–1.47), and 1.28 (1.06–1.55; Ptrend < .001). The Lp(a) concordance was 86% (<80th percentile) and 53% (≥80th percentile). Conclusions: First-degree relatives of individuals with elevated Lp(a) levels have a higher incidence of MACE. Cascade screening could be a feasible strategy to identify FDR at heightened risk.


  • Open Access

    Elevated lipoprotein(a) and progression of aortic stenosis measured by Doppler echocardiography: A population‐based cohort study

    by Jonas Brinck, Karin Littmann, Daniel Eriksson Hogling, Linnea Widman, Kenneth Caidahl, Maria Eriksson, Jonas Johnson, Karolina Szummer, Magnus Bäck


  • Open Access

    Development and implementation of a digiphysical screening model with nationwide reach to diagnose familial hypercholesterolemia

    by Karin Littmann, Gustav Kindborg, Matthias Lidin, Linda Mellbin, Daniel Eriksson Hogling, Jonas Brinck

    Background: Familial hypercholesterolemia (FH) is a hereditary dyslipidemia that confers a severely elevated risk for development of early atherosclerotic cardiovascular disease if left untreated. FH is underdiagnosed in most countries including Sweden. Aim: To develop and evaluate the implementation of a digiphysical screening model to diagnose FH in the clinical routine. Methods: A digiphysical screening model for FH, containing digital and physical related activities was developed and fully implemented in routine clinical care in the Stockholm region, Sweden 2022. The centerpiece of the model is a tailormade interactive web-based platform designed to facilitate communication and secure medical information exchange between its participants and the healthcare professionals. The screening model includes, (i) cascade screening of relatives to patients with a confirmed FH diagnosis and (ii) systematic selective screening of patients with established atherosclerotic coronary artery disease. Results: Until October 2023, 338 index patients were included in the cascade screening. They invited 954 relatives nationwide, 616 (64.6%) accepted participation, 346 (36.3%) were completely screened, and 141 (14.8%) have received a FH diagnosis (40.8% of all completely screened). Selective screening was performed in 2867 patients with coronary artery disease, 355 (12.4%) were identified with increased risk for FH and underwent a genetic test. Of these, 153 (3.8%) had a genetic test result and 52 (1.8%) were diagnosed with FH. Conclusions: A digiphysical screening model with a nationwide reach to diagnose FH was successfully implemented in routine clinical care. The model has potential to facilitate FH screening and provide health economic benefits long term.

  • Open Access

    Extending the Lund-Malmö creatinine-based GFR equation to cystatin C – validation results from the European Kidney Function Consortium (EKFC) cohort of children and adults

    by Jonas Björk, Ulf Nyman, Ulla Berg, Arend Bökenkamp, Etienne Cavalier, Natalie Ebert, Björn O. Eriksen, Laurence Derain Dubourg, Karolien Goffin, Anders Grubb, et al.

    The aim of the present study was to extend the creatinine-based Lund-Malmö GFR equation for use with rescaled cystatin C (r-LMRCys) and validate it against measured GFR (mGFR) in the EKFC cystatin C cohort of children (n = 2,293) and adults (n = 7,727). Rescaling was obtained by dividing each biomarker by a Q-value, representing the population-specific median biomarker level among healthy individuals. Validation included median bias/precision/accuracy (percent estimates within ±30% of mGFR, P30). Performance was compared with the EKFC-equation (EKFCCys), the CAPA cystatin C equation, the corresponding equations based on rescaled creatinine (r-LMRCr and EKFCCr) and the arithmetic mean of r-LMRCr and CAPA (r-LMRCr+CAPA), r-LMRCr and r-LMRCys (r-LMRMean), and EKFCCr and EKFCCys (EKFCMean). The overall P30 of r-LMRCys in adults was 86.2% (95% CI 85.4%-86.9%), which was 6.6 percentage points (pp; 95% CI 5.8-7.4 pp) higher than for CAPA and similar to r-LMRCr (P30 87.4%, 95% CI 86.6%-88.1%). r-LMRCys and EKFCCys exhibited similar performance both overall and across subgroups of age, sex, GFR and BMI and in children. All three arithmetic mean equations had similar P30-accuracy and generally performed better than the corresponding single-marker equations. Our results show that the Lund-Malmö GFR equation can be adapted for use with rescaled cystatin C with performance that is similar to the best-performing equations based on rescaled creatinine. The generality of the applied biomarker rescaling principle implies that the future demand for population- and biomarker-specific GFR estimating equations can be expected to decrease substantially.


  • Open Access

    Estimating glomerular filtration in young people

    by Pierre Delanaye, Pierre Delanaye, Laurence Derain-Dubourg, Laurence Derain-Dubourg, Jonas Björk, Jonas Björk, Marie Courbebaisse, Marie Courbebaisse, Lionel Couzi, Lionel Couzi, et al.

    Creatinine-based equations are the most used to estimate glomerular filtration rate (eGFR). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), the re-expressed Lund-Malmö Revised (r-LMR) and the European Kidney Function Consortium (EKFC) equations are the most validated. The EKFC and r-LMR equations have been suggested to have better performances in young adults, but this is debated. We collected data (GFR) measured by clearance of an exogenous marker (reference method), serum creatinine, age and sex from 2366 young adults (aged between 18 and 25 years) both from Europe and the USA. In the European cohorts (n = 1892), the bias (in mL/min/1.73 m²) was systematically better for the EKFC and r-LMR equations compared with the CKD-EPI equation [2.28, 95% confidence interval (1.59; 2.91), –2.50 (–3.85; –1.76), 17.41 (16.49; 18.47), respectively]. The percentage of estimated GFR within 30% of measured GFR (P30) was also better for EKFC and r-LMR equations compared with the CKD-EPI equation [84.4% (82.8; 86.0), 87.2% (85.7; 88.7) and 65.4% (63.3; 67.6), respectively]. In the US cohorts (n = 474), the bias for the EKFC and r-LMR equations was better than for the CKD-EPI equation in the non-Black population [0.97 (–1.69; 3.06), –2.62 (–5.14; –1.43) and 7.74 (5.97; 9.63), respectively], whereas the bias was similar in Black US individuals. P30 results were not different between the three equations in US cohorts. Analyses in sub-populations confirmed these results, except in individuals with high GFR levels (GFR ≥120 mL/min/1.73 m²) for whom the CKD-EPI equation might have a lower bias. We demonstrated that both the EKFC and r-LMR creatinine-based equations have a better performance than the CKD-EPI equation in a young population. The only exception might be in patients with hyperfiltration.


  • Open Access

    Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors—design and rationale of the Stockholm hyperTRIglyceridaemia REGister study

    by Daniel P Andersson, Karin Littmann, Gustav Kindborg, Daniel Eklund, Kristina Sejersen, Jane Yan, Daniel Eriksson Hogling, Paolo Parini, Jonas Brinck

    Aims: Hypertriglyceridaemia (hTG) is associated with atherosclerotic cardiovascular disease, pancreatitis, and non-alcoholic fatty liver disease (NAFLD) in large population-based studies. The understanding of the impact of hereditary hTG and cardiometabolic disease status on the development of hTG and its associated cardiometabolic outcomes is more limited. We aimed to establish a multigenerational cohort to enable studies of the relationship between hTG, cardiometabolic disease and hereditary factors. Methods and results: The population-based observational Stockholm hyperTRIglyceridaemia REGister (STRIREG) study includes 1 460 184 index individuals who have measured plasma triglycerides in the clinical routine in Region Stockholm, Sweden, between 1 January 2000 and 31 December 2021. The laboratory measurements also included basic haematology, blood lipid panel, liver function tests, and HbA1c. Using the Swedish Multi-Generation register, 2 147 635 parents and siblings to the indexes were identified to form the complete study cohort. Laboratory data from participants were combined with data from several national registers that provided information on the cause of death, medical diagnoses, dispensed medicines, and socioeconomic factors including country of birth, education level, and marital status. Conclusion: The multi-generational longitudinal STRIREG cohort provides a unique opportunity to investigate different aspects of hTG as well as heredity for other metabolic diseases. Important outcome measures include mortality, cardiovascular mortality, major cardiovascular events, development of incident diabetes, and NAFLD. The STRIREG study will provide a deeper understanding of the impact of hereditary factors and associated cardiometabolic complications.


  • Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up

    by Karin Littmann, Emil Hagström, Henrike Häbel, Matteo Bottai, Mats Eriksson, Paolo Parini, Jonas Brinck

    To investigate plasma lipoprotein(a) [Lp(a)] levels measured in routine clinical care and their association with mortality and cardiovascular disease. This retrospective registry-based observational cohort study includes all individuals with plasma Lp(a) results measured at the Karolinska University Laboratory 2003–17. Outcome data were captured in national outcome registries. Levels of Lp(a) expressed in mass or molar units were examined separately. In adjusted Cox regression models, association between deciles of plasma Lp(a) concentrations, mortality, and cardiovascular outcomes were assessed. A total of 23 398 individuals [52% females, mean (standard deviation) age 55.5 (17.2) years, median Lp(a) levels 17 mg/dL or 19.5 nmol/L] were included. Individuals with an Lp(a) level >90th decile (>90 mg/dL or >180 nmol/L) had hazard ratios (95% confidence interval) of 1.25 (1.05–1.50) for major adverse cardiovascular events (P = 0.013), 1.37 (1.14–1.64) for atherosclerotic cardiovascular disease (P = 0.001), and 1.62 (1.28–2.05) for coronary artery disease (P ≤ 0.001), compared to individuals with Lp(a) ≤50th decile. No association between Lp(a) and mortality, peripheral artery disease, or ischaemic stroke was observed. High Lp(a) levels are associated with adverse cardiovascular disease outcomes also in individuals with Lp(a) measured in routine clinical care. This supports the 2019 ESC/EAS recommendation to measure Lp(a) at least once during lifetime to assess cardiovascular risk and implies the need for intensive preventive therapy in patients with elevated Lp(a).


  • Open Access

    Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report

    by Simon Sjuls, Ulf Jensen, Karin Littmann, Annette Bruchfeld, Jonas Brinck

    Background: Nephrotic syndrome causes severe hypercholesterolaemia due to increased production and altered clearance of lipoproteins from the liver. It is challenging for patients with nephrotic syndrome and coronary heart disease to meet LDL-cholesterol (LDL-C) goals for secondary prevention with conventional lipid-lowering therapy. Case summary: We present a man with nephrotic syndrome caused by focal segmental glomerular sclerosis (FSGS) and hypercholesterolaemia. He presented at the emergency room (ER) with an ST-elevation myocardial infarction at the age of 26. On follow-up, the patient had persistent hypercholesterolaemia [LDL-C 3.9 mmol/L and lipoprotein(a) 308 nmol/L] despite a combination of lipid-lowering therapy with atorvastatin 80 mg/day and ezetimibe 10 mg/day. Addition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitory antibody evolocumab 140 mg bi-monthly did not improve cholesterol levels. However, after addition of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin 10 mg/day on top of other anti-proteinuric treatments, the patient’s proteinuria was reduced and a dramatic drop in LDL-C level by 3.2–0.6 mmol/L (−81%) was observed when evolocumab was re-introduced. Discussion: We show that target LDL-C levels were obtained in this patient with therapy-resistant FSGS and hypercholesterolaemia following multi-pharmacological treatment with SGLT2 and PCSK9 inhibitors on top of conventional lipid-lowering therapy. The SGLT2-inhibitor reduced proteinuria and, speculatively, also reduced urinary loss of PCSK9-antibody. Therefore, in patients with nephrotic syndrome and cardiovascular disease novel therapeutic options to manage proteinuria could be considered to improve the efficacy of the lipid-lowering therapy, especially when the protein-based PCSK9 inhibitors are used.


  • Evaluation of global haemostatic assays and fibrin structure in patients with pre‐eclampsia

    by Sanja Lalic‐Cosic, Violeta Dopsaj, Mirjana Kovac, Iva Pruner, Karin Littmann, Vesna Mandic‐Markovic, Zeljko Mikovic, Aleksandra Antovic

    Introduction: Haemostatic balance shifted towards hypercoagulability in normal pregnancy is even more pronounced in pre‐eclampsia (P‐EC). The aim of this study was to analyse haemostatic disturbances and fibrin clot properties in women with pre‐eclampsia and to investigate their association with maternal and foetal outcomes.Methods: Forty‐six pregnant women diagnosed with pre‐eclampsia were included in the study, with blood sampling done on the morning following admission to hospital, as well as after delivery (mean duration 4.8 days). Two global haemostatic assays—endogenous thrombin potential (ETP) and assay of overall haemostatic potential (OHP)—were employed, including fibrin clot turbidity measurements and scanning electron microscopy (SEM) of representative samples.Results: Three thrombin generation parameters (ETP, t_lag and peak height) and OHP were significantly increased in pre‐eclampsia compared with controls, whereas overall fibrinolytic potential (OFP—determined as a parameter of the OHP assay) had significantly lower values. Clot lysis time was significantly prolonged in patients with pre‐eclampsia. In the pre‐eclamptic group after delivery, we observed a significant elevation in the peak height and a reduction in the time to peak and OFP compared with values before delivery. Pre‐eclamptic patients with renal complications had significantly higher values for ETP, peak height and D‐dimer. Turbidity measurements and SEM revealed dense fibrin structure in patients with pre‐eclampsia.Conclusion: Patients with pre‐eclampsia have enhanced coagulation and impaired fibrinolysis before, and even after, delivery. In particular, the presence of multi‐organ dysfunction, such as renal dysfunction, may be associated with increased thrombin generation in pre‐eclampsia.